nach oben

Drugs & Aging

Erschienen in:

01.08.2002 | Review Article

Outcomes of Lipid-Lowering Treatment in Postmenopausal Women

verfasst von: Dr John C. LaRosa

Erschienen in: Drugs & Aging | Ausgabe 8/2002

Einloggen, um Zugang zu erhalten

Abstract

Elevated triglycerides and low high-density lipoprotein (HDL) levels are more important coronary risk factors in women, and elevated low-density lipoprotein (LDL) levels less important in women, than men. There is clear-cut evidence in clinical trials that the benefit of cholesterol lowering in women and men is virtually identical.

Modifiers of lipids and lipoproteins in women include diabetes mellitus, body-weight and its distribution, and menopausal status. Diabetes is a more powerful predictor of risk in women than men. This may relate to the importance of elevated triglycerides as a risk factor in women, and to the effects of lipoprotein glycosylation, which lead to increased susceptibility to arterial deposition of LDL and decreased reverse cholesterol transport with HDL.

Therapy for lipoprotein disorders in women and men is identical. For the overwhelming majority of patients, treatment with statin therapy is both highly efficacious and well tolerated.

Bass KM, Newschaffer CJ, Klag MJ, et al. Plasma lipoprotein levels as predictors of cardiovascular death in women. Arch Intern Med 1993; 153: 2209–16PubMedCrossRef

LaRosa JC. Triglycerides and coronary risk in women and the elderly. Arch Intern Med 1997; 157: 961–8PubMedCrossRef

LaRosa JC. The pharmacology and effectiveness of specific lipid-active drugs: estrogen/sex steroids. Coron Artery Dis 1996; 7: 683–8PubMedCrossRef

Kannel WB. Nutrition and the occurrence and prevention of cardiovascular disease in the elderly. Nutr Rev 1984; 46: 68–78CrossRef

World Health Organization. Japan outscores USA in longevity ranking. USA Today 2000 June 5; Sect. D: 6

Manolio TA, Pearson TA, Wenger NK, et al. Cholesterol and heart disease in older persons and women: review of an NHLBI workshop. Ann Epidemiol 1992; 2: 161–76PubMedCrossRef

LaRosa JC. Cholesterol agonistics. Ann Intern Med 1996; 124: 505–8PubMed

LaRosa JC, He J, Vupputuri S. Effects of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 1999; 282: 2340–6PubMedCrossRef

Sandkamp M, Assmann G. Lipoprotein(a) in PRO-CAM participants and young myocardial infarction survivors. In: Scanu AM, editor. Lipoprotein(a). New York (NY): Academic Press, 1990: 205–9

10.

Brewer HB. Effectiveness of diet and drugs in the treatment of patients with elevated Lp(a) levels. In: Scanu AM, editor. Lipoprotein(a). New York: Academic Press, 1990: 211–20

11.

Krolewski AS, Warram JH, Valsania P, et al. Evolving natural history of coronary artery disease in diabetes mellitus. Am J Med 1991; 90(2A): 56S–61SPubMedCrossRef

12.

Verges BL. Dyslipidaemia in diabetes mellitus: review of the main lipoprotein abnormalities and their consequences on the development of atherogenesis. Diabetes Metab 1999; 25(S3): 32–40PubMed

13.

Soler JT, Folsom AR, Kushi LH, et al. Association of body fat distribution with plasma lipids, lipoproteins, apolipoproteins A-1 and B in postmenopausal women. J Clin Epidemiol 1988; 41: 1075–81PubMedCrossRef

14.

Lapidus L, Bengtsson C, Larsson B, et al. Distribution of adipose tissue and risk of cardiovascular disease and death: a 12-year follow-up of participants in the population study of women in Gothenburg, Sweden. BMJ 1984; 289: 1257–61PubMedCrossRef

15.

Grodin JM, Siiteri PK, MacDonald PC. Source of estrogen production in postmenopausal women. J Clin Endocrinol Metab 1973; 36: 207–14PubMedCrossRef

16.

Barnard RJ. Effects of life-style modification on serum lipids. Arch Intern Med 1991; 151: 1389–94PubMedCrossRef

17.

Bush TL. The epidemiology of cardiovascular disease in postmenopausal women. Ann N Y Acad Sci 1990; 592: 263–71PubMedCrossRef

18.

van der Schouw YT, van der Graaf Y, Steyerberg EW, et al. Age at menopause as a risk factor for cardiovascular mortality. Lancet 1996; 347: 714–8PubMedCrossRef

19.

PEPI Investigators. Effects of estrogen or estrogen-progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995; 273: 199–208CrossRef

20.

Adams MR, Register TC, Golden DL, et al. Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis. Arterioscler Thromb Vasc Biol 1997; 17: 217–21PubMedCrossRef

21.

Psaty BM, Heckbert SR, Atkins D, et al. The risk of myocardial infarction associated with the combined use of estrogens and progestins in postmenopausal women. Arch Intern Med 1994; 154: 1333–9PubMedCrossRef

22.

Hulley S, Grady D, Bush T, et al., for the Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998; 280: 605–13PubMedCrossRef

23.

Herrington DM, Reboussin DM, Brosnihan KB, et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000; 343: 522–9PubMedCrossRef

24.

Wood D, De Backer G, Faergeman O, et al., and Task Force Members. Prevention of coronary heart disease in clinical practice. Eur Heart J 1998; 19: 1434–503CrossRef

25.

Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486–97CrossRef

26.

Robins SJ, Collins D, Wittes JT, et al., for the VA-HIT Study Group. Relation of gemfibrozil treatment and lipid levels with major coronary events. JAMA 2001; 285: 1585–91PubMedCrossRef

27.

BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 2000; 102: 21–7CrossRef

28.

Mensink RP, Katan MB. Effect of monounsaturated fatty acids versus complex carbohydrates on high-density lipoproteins in healthy men and women. Lancet 1987; 8525: 122–5CrossRef

29.

Masarei JRL, Rouse IL, Lynch WJ, et al. Effects of a lacto-ovo vegetarian diet on serum concentration of cholesterol, triglyceride, HDL-C, HDL2-C, HDL3-C, apoprotein-B, and Lp(a). Am J Clin Nutr 1984; 40: 468–78PubMed

30.

Ernst N, Bowen P, Fisher M, et al. Changes in plasma lipids and lipoproteins after a modified fat diet. Lancet 1980; I: 111–3CrossRef

31.

Lokey EA, Tran ZV. Effects of exercise training on serum lipid and lipoprotein concentrations in women: a meta-analysis. Int J Sports Med 1989; 10: 424–9PubMedCrossRef

32.

Hartung GH, Moore CE, Mitchell R, et al. Relationship of menopausal status and exercise level to HDL cholesterol in women. Exp Aging Res 1984; 10: 13–8CrossRef

33.

Knopp RH. Drug treatment of lipid disorders. N Engl J Med 1999; 341: 498–511PubMedCrossRef

Titel: Outcomes of Lipid-Lowering Treatment in Postmenopausal Women
verfasst von: Dr John C. LaRosa
Publikationsdatum: 01.08.2002
Verlag: Springer International Publishing
Erschienen in: Drugs & Aging / Ausgabe 8/2002
Print ISSN: 1170-229X
Elektronische ISSN: 1179-1969
DOI: https://doi.org/10.2165/00002512-200219080-00005

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Strenge Blutdruckeinstellung lohnt auch im Alter noch

30.04.2024 Arterielle Hypertonie Nachrichten

Ältere Frauen, die von chronischen Erkrankungen weitgehend verschont sind, haben offenbar die besten Chancen, ihren 90. Geburtstag zu erleben, wenn ihr systolischer Blutdruck < 130 mmHg liegt. Das scheint selbst für 80-Jährige noch zu gelten.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2002

Gene Therapy for Renal Disorders

Relapse Prevention and Maintaining Abstinence in Older Adults with Alcohol-Use Disorders

Acute Myeloid Leukaemia

Potential of Transdermal Drug Delivery in Parkinson’s Disease